Aura Biosciences, Inc. (AURA) Dividend Safety
- Dividend payout ratio · 12 months: Value (m); Formula and calculation Cash dividends paid / net income. Period ending 2026-06-30..
Dividend safety
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Dividend payout ratio · 12 months | (m) | Cash dividends paid / net income. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Dividend payments · 12 months | (m) | |
| Net income · 12 months | -131.01M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Dividend payments · 12 months (USD) | Net income · 12 months (USD) | Dividend payout |
|---|---|---|---|
| 2026-06-30 | (m) | $-131.01M | (m) |
| 2026-03-31 | (m) | $-112.39M | (m) |
| 2025-12-31 | (m) | $-106.19M | (m) |
| 2025-09-30 | (m) | $-106.47M | (m) |
| 2025-06-30 | (m) | $-101.38M | (m) |
| 2025-03-31 | (m) | $-94.70M | (m) |
| 2024-12-31 | (m) | $-86.92M | (m) |
| 2024-09-30 | (m) | $-83.22M | (m) |
| 2024-06-30 | (m) | $-80.69M | (m) |
| 2024-03-31 | (m) | $-78.65M | (m) |
| 2023-12-31 | (m) | $-76.41M | (m) |
| 2023-09-30 | (m) | $-70.84M | (m) |
| 2023-06-30 | (m) | $-68.22M | (m) |
| 2023-03-31 | (m) | $-63.39M | (m) |
| 2022-12-31 | (m) | $-58.76M | (m) |
| 2022-09-30 | (m) | $-53.84M | (m) |
| 2022-06-30 | (m) | $-46.77M | (m) |
| 2022-03-31 | (m) | $-42.16M | (m) |
| 2021-12-31 | (m) | $-35.25M | (m) |
| 2021-09-30 | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) |
| 2020-12-31 | (m) | $-22.21M | (m) |
| 2020-09-30 | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |